Safety Warning: Pharmaceutical-Grade Peptides Required (503A Pharmacy)
The speaker issues a sourcing warning, stating that research-grade peptides are not equivalent to pharmaceutical-grade peptides and advising viewers to obtain peptides exclusively from a 503A compounding pharmacy. This is framed as a critical safety or quality rule. No specific data on contaminant risks or purity differences between grades is provided.
High-Dose TB-500 Protocol for Serious Injuries
For more serious injuries, the speaker describes escalating TB-500 dosing up to 2,000 micrograms, compared to the standard 500 micrograms daily. This higher dose is described as part of their clinical practice for select cases. No safety data, titration guidance, or study references are provided for this elevated dose.
Systemic Biodistribution: Injection Site Independence
The speaker claims that both BPC-157 and TB-500 work systemically, meaning injection does not need to occur directly at the injury site for the peptides to be effective. Despite this, the speaker acknowledges that injecting at the injury site is common practice, including in his own use. No pharmacokinetic studies are cited.
The Wolverine Stack: BPC-157 + TB-500 Combination Protocol
The speaker recommends combining BPC-157 and TB-500 — referred to as the 'Wolverine stack' — for nagging injuries, slow recovery, and gut issues. The standard protocol is 500 micrograms of each peptide daily for a 3-month cycle. This is presented as a clinical recommendation without citation of controlled studies.
TB-500 Mechanism of Action: Angiogenesis and Cellular Migration
TB-500 is described as promoting new blood vessel growth (angiogenesis) and improving cellular migration to damaged areas. These mechanisms are presented as complementary to BPC-157's effects. No studies are cited to support these claims.
Warning against simultaneous multi-peptide stacking
Dr. Jones warns that taking five or more peptides concurrently — a common biohacker practice — leads to wasted money and minimal results. This is framed as a safety/efficacy warning based on his clinical observations, though no adverse effects are specified beyond lack of efficacy.
Phased peptide protocol: Foundation → Healing → Optimization → Anti-Aging
Dr. Jones's clinic uses a sequential phasing approach rather than simultaneous stacking: (1) Foundation, (2) Healing, (3) Optimization, (4) Anti-aging. He warns that skipping phases wastes money and rushing the stack yields no results. No specific peptide-to-phase assignments or dosages are provided in this transcript.
Peptide sequencing order matters more than the stack composition
Dr. Jones argues that the order in which peptides are introduced matters more than which peptides are combined. He observes that people taking five peptides simultaneously (BPC-157, TB-500, GH secretagogues, fat loss peptides, anti-aging compounds) often get poor results. No dosages mentioned.
Warning: Peptides mask autoimmune root cause in lupus
Dr. Jones warns that relying on peptide therapies without addressing the underlying autoimmune drivers of lupus leads to expensive, chronic dependency on repeated peptide cycles. He argues that addressing root causes (gut health, inflammation, nutrient deficiencies, dietary triggers, nervous system) reduces the need for ongoing peptide use, making treatment more sustainable.
Lupus patients using BPC-157 and TB-500 as symptom management
Dr. Jones observes that many lupus patients are using peptide therapies like BPC-157 and TB-500 (referred to collectively with 'the Wolverine' stack) to manage joint pain and inflammation symptoms. He states he'd prefer patients use these over harmful biologics or corticosteroids, but cautions that they are still masking the underlying autoimmune problem rather than addressing root cause.
Sourcing Warning: Pharmacy-Grade vs. Research Chemical Peptides
Dr. Jones warns that peptide sourcing is more important than the peptide selection itself. He states that research-grade chemicals lack consistency and recommends only pharmacy-grade peptides. This is positioned as a safety and efficacy concern — implying that research chemicals may be underdosed, contaminated, or inconsistent in formulation.
TB-500 Mechanism: Repair Cell Recruitment
The second peptide in the stack is described as flooding the injury area with repair cells. Based on known mechanisms, this cell-migration and repair-cell recruitment property aligns with TB-500 (Thymosin Beta-4 fragment). No dosage or frequency is specified.
The Wolverine Stack: BPC-157 + TB-500 Combination for Injury Repair
Dr. Jones describes a peptide stack he calls 'The Wolverine Stack' combining BPC-157 and TB-500 for injury healing. He claims the two peptides work synergistically — one promotes angiogenesis (new blood vessel formation) into the injury site, while the other recruits repair cells to the area. No specific dosages or injection protocols are provided.
TB-500 effectiveness is determined by total weekly dose, not dosing frequency
For TB-500, the critical variable is the cumulative weekly dose rather than dosing frequency. Smaller daily doses provide comparable weekly exposure to larger twice-weekly doses. This is attributed to TB-500's intracellular mechanism where actin binding sustains activity beyond plasma clearance.
BPC-157 + TB-500 blend: twice-weekly dosing is also effective
Twice-weekly dosing of the BPC-157/TB-500 blend can also work because the TB-500 component maintains effectiveness through its intracellular mechanism regardless of frequency. However, this is suboptimal for the BPC-157 component. The speaker notes either strategy works and comes down to personal preference.
BPC-157 + TB-500 blend: daily dosing is the optimal protocol
When using a pre-made BPC-157/TB-500 blend, daily dosing is recommended. Daily administration does not reduce TB-500 effectiveness (since total weekly exposure remains comparable) while ensuring maximum BPC-157 benefit due to its presence-dependent mechanism. The blend makes daily dosing the simpler and more effective strategy.
TB-500 can be dosed twice per week when used separately
When used as a standalone peptide (not in a blend), TB-500 only needs to be administered twice per week. This less frequent dosing schedule is sufficient because its intracellular actin-binding mechanism provides sustained activity regardless of plasma clearance. What matters is the total weekly dose, not constant plasma levels.
TB-500 mechanism: intracellular actin binding for sustained tissue repair
TB-500 works by entering cells and binding to actin, a structural protein involved in tissue repair. Once bound intracellularly, TB-500 continues to promote repair processes independent of its plasma concentration. This intracellular depot effect distinguishes it from BPC-157's presence-dependent mechanism.
TB-500 has a short plasma half-life (~1-2 hours) but prolonged intracellular action
TB-500 has a plasma half-life of only 1-2 hours, similar to BPC-157. However, unlike BPC-157, TB-500 enters cells and binds to actin (a structural protein involved in repair), allowing it to continue driving tissue repair even after the peptide has cleared from the bloodstream.
BPC-157 and TB-500 Angiogenesis Is Not Cancer-Promoting
Dr. Bachmeyer briefly addresses concerns about BPC-157 and TB-500 causing cancer via angiogenesis. He states that the angiogenesis promoted by these peptides is controlled, well-regulated biological growth — not the erratic, uncontrolled growth that cancer requires. He urges listeners to 'stop and smell the biology.'
TB-500 does not cause cancer despite VEGF upregulation
Dr. Bachmeyer explicitly addresses the concern that VEGF upregulation could promote cancer, stating TB-500 does not cause cancer and is in fact anti-cancer, despite its mechanism of upregulating vascular endothelial growth factor.
TB-500 cycling requirement — cannot take daily indefinitely
Dr. Bachmeyer warns that TB-500 cannot be taken every day forever and needs to be cycled. No specific cycling protocol (on/off duration) was provided in this portion of the transcript.
TB-500 is pleiotropic — four primary mechanisms of action
TB-500 acts through four primary mechanisms simultaneously: (1) increases angiogenesis, (2) mitigates inflammation, (3) inhibits fibroblast activation and collagen deposition, and (4) promotes cardiac stem cell/progenitor cell mobilization. This pleiotropic nature addresses disease at the mechanism level rather than the symptom level.
TB-500 is based on thymosin beta-4 — a naturally occurring actin-regulating peptide
TB-500 is based on thymosin beta-4, a naturally occurring 43-amino-acid protein identified by Schroeder in 1981. It is an actin-regulating peptide that binds to actin monomers, sequesters them to prevent uncontrolled polymerization, and makes them available for controlled redeployment when cells need to rebuild or migrate.
TB-500 for atrial fibrillation and cardiac conduction problems
TB-500 is specifically mentioned as relevant for atrial fibrillation (AFib), cardiac conduction abnormalities, enlarged heart, ejection fraction problems, and ventricular problems. These are categorized as tissue damage problems requiring tissue rebuilding rather than anti-inflammatory intervention alone. No dosage or protocol details provided in the available transcript.
KPV + TB-500 stack for comprehensive cardiovascular disease resolution
The core thesis is that KPV addresses the root cause of cardiovascular disease (chronic systemic inflammation — restoring endothelial function, resolving inflammation, stabilizing plaque) while TB-500 addresses downstream tissue damage (cardiac scarring, fibrosis, structural remodeling). Together they are positioned as a comprehensive two-pronged solution. No specific dosages or protocol timing mentioned in the available transcript.
TB-500 rebuilds damaged cardiac tissue post-myocardial infarction
TB-500 is presented as a compound that literally rebuilds cardiac tissue damaged by myocardial infarction. After an MI, cardiomyocytes die via necrosis and fibroblasts lay down disorganized collagen scar tissue that cannot contract. TB-500 is positioned as the solution for existing tissue damage including scar tissue, myocardial fibrosis, ejection fraction problems, enlarged heart, and pericardium-related issues. No specific dosages mentioned in this segment.
Safety claim: cannot overdose on KPV, BPC-157, or TB-500
Dr. Bachmeyer claims that you cannot overdose and die from KPV, BPC-157, or TB-500, contrasting these with statins, NSAIDs, and prednisone which can cause fatal overdose. He argues that since the body naturally produces the parent compounds (e.g., alpha-MSH for KPV), they are inherently safer than synthetic pharmaceuticals.
TB-500 desensitization warning from oversaturation
Dr. Bachmeyer warns that taking TB-500 more frequently than its ~5-day half-life allows leads to receptor oversaturation, desensitization, and 'biology gets decimated.' He specifically states micro-dosing TB-500 (as would happen in a daily blend) just 'tickles the receptors and doesn't work.'
BPC-157, TB-500, and GHK-Cu blend criticism — incompatible half-lives
Dr. Bachmeyer argues blends of BPC-157, TB-500, and GHK-Cu are ineffective for two reasons: (1) they get corrupted inside the vial, and (2) incompatible half-lives make co-administration illogical. TB-500 has a ~5-day half-life (dosed near-weekly) while BPC-157 has a ~1-day half-life (dosed daily). You either micro-dose TB-500 (which he says just 'tickles receptors' and doesn't work) or skip days of BPC-157. He also states GHK-Cu 'demolishes' in blends (copper interaction).